Europe approves new use for Pfizer's Celebrex drug
LONDON, Feb 23 (Reuters) - Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz) said on Friday that 17 European countries had agreed to extend the approved use of its Celebrex drug to include symptomatic relief of ankylosing spondylitis in adults.
The decision makes Celebrex the first so-called COX-2 inhibitor to be approved for the disease, a form of arthritis that affects the spine.
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Entertainment
Zardari Pakistan's new president